Ogura H, Hisakawa H, Kawakubo K, Kubota H, Shimanouchi Y, Matsumoto K, Tomoda T, Tone Y, Kurashige T
Department of Pediatrics, Kochi Medical School.
Jpn J Antibiot. 1989 Mar;42(3):766-72.
Sulbactam (SBT) is a new derivative of the basic penicillin nucleus. It effectively and irreversibly inhibits several important bacterial beta-lactamases and displays synergistic effects against the resistant organisms when co-administered with ampicillin (ABPC). SBT/ABPC, which is a fixed combination of SBT and ABPC in a 1:2 ratio, was studied for clinical efficacy in the field of pediatrics. Patients treated were infants and children ranging from 12 days to 13 years and 2 months old suffering from acute tonsillitis in 2 cases, acute bronchitis in 2 cases, septicemia in 2 cases, acute enteritis, acute pyelonephritis and osteomyelitis in 1 case each, a total of 9 cases. SBT/ABPC was administered 100-300 mg/kg in daily doses and durations of treatment ranged from 4 to 17 days. Clinical results were "excellent" in 6 and "good" in 2: the efficacy rate was 88.9% or 8 cases out of 9. Neither clinical side effects nor abnormal laboratory findings obviously attributable to SBT/ABPC were observed in any cases.
舒巴坦（SBT）是基本青霉素核的一种新衍生物。它能有效且不可逆地抑制多种重要的细菌β-内酰胺酶，与氨苄西林（ABPC）联合使用时，对耐药菌显示出协同作用。SBT/ABPC是SBT和ABPC按1:2比例的固定组合，已在儿科领域研究其临床疗效。治疗的患者为12天至13岁2个月的婴幼儿和儿童，其中急性扁桃体炎2例，急性支气管炎2例，败血症2例，急性肠炎、急性肾盂肾炎和骨髓炎各1例，共9例。SBT/ABPC的日剂量为100 - 300mg/kg，治疗疗程为4至17天。临床结果为6例“优”，2例“良”：有效率为88.9%，即9例中有8例有效。所有病例均未观察到明显归因于SBT/ABPC的临床副作用或实验室异常结果。
